Pure Global
NCT06342336

HS-IT101 Injection in the Treatment of Advanced Solid Tumors

Single Arm, Phase I Clinical Study of HS-IT101 Injection in the Treatment of Advanced Solid Tumors
Qingdao Sino-Cell Biomedicine Co., Ltd.·Phase 1·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Solid Tumor
Drug/Device/Intervention
HS-IT101 Injection
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Qingdao Sino-Cell Biomedicine Co., Ltd.
Location
Beijing, China
Timeline & enrollment
Phase
Phase 1
Start date
Jan 18, 2024
End date
Mar 31, 2028
Enrollment
44 participants
Primary outcome

Adverse Events (AE),Serious Adverse Events (SAE)

Summary

Single-arm, open-label,interventional study evaluating adoptive cell therapy (ACT) with
 autologous tumor-infiltrating lymphocyte (TIL) infusion (HS-IT101) after lymphodepletion
 preparative with fludarabine and cyclophosphamide regimen, followed by IL-2, for the
 treatment of patients with advanced solid tumor.

ICD-10 classifications
Malignant neoplasm: Connective and soft tissue, unspecifiedCarcinoma in situ, unspecifiedMalignant neoplasm: ParametriumMalignant neoplasm of other connective and soft tissueMalignant neoplasm: Lip, unspecified, inner aspect
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06342336
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06342336 through Pure Global AI's free database. This Phase 1 trial is sponsored by Qingdao Sino-Cell Biomedicine Co., Ltd. and is currently Recruiting. The study focuses on Solid Tumor. Target enrollment is 44 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.